NCT03400124 is a NA clinical trial of ISBCS in Bilateral Cataract, sponsored by Maastricht University Medical Center.

Who is sponsoring NCT03400124?

NCT03400124 is sponsored by Maastricht University Medical Center.

What drugs are being tested in NCT03400124?

Interventions in NCT03400124: ISBCS, DSBCS.

What condition does NCT03400124 study?

NCT03400124 studies Bilateral Cataract.

Is NCT03400124 still recruiting?

NCT03400124 is currently completed. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT03400124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cost-effectiveness of ISBCS vs. DSBCS

Completed NA Last updated 5 September 2021

What this trial tests

NA trial testing ISBCS in Bilateral Cataract in 858 participants. Completed in 1 February 2021.

Timeline

1 September 2018

Primary endpoint
1 October 2020

1 February 2021

Quick facts

Lead sponsor	Maastricht University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	858
Start date	1 September 2018
Primary completion	1 October 2020
Estimated completion	1 February 2021
Sites	1 location across Netherlands

Drugs / interventions tested

ISBCS
DSBCS

Conditions studied

Bilateral Cataract — all drugs for Bilateral Cataract →

Sponsor

Maastricht University Medical Center

Who can join

18 and older, any sex, with Bilateral Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effectiveness and costs of immediately sequential bilateral cataract surgery (ISBCS) compared to delayed sequential bilateral cataract surgery (DSBCS) in order to determine whether ISBCS is an effective and cost-effective alternative to DSBCS.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
Spekreijse L, Simons R, Winkens B, van den Biggelaar F, et al · · 2023 · cited 30× · PMID 37201546 · DOI 10.1016/s0140-6736(23)00525-1
Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts.
Dickman MM, Spekreijse LS, Winkens B, Schouten JS, et al · · 2022 · cited 21× · PMID 35467755 · DOI 10.1002/14651858.cd013270.pub2
Cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (the BICAT-NL study): study design of a prospective multicenter randomised controlled trial.
Spekreijse LS, Simons RWP, Winkens B, van den Biggelaar FJHM, et al · · 2020 · cited 9× · PMID 32600295 · DOI 10.1186/s12886-020-01521-x

Verify or expand the search:

Other Maastricht University Medical Center trials

Trials by the same sponsor.

NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03400124 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03400124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing